EcoDrugPlus

5-Hydroxytryptamine Receptor 1a-Beta-Like

Ensembl ID : ENSOKIG00005012371
Gene Symbol: LOC109868154
3 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSOKIG00005001759
Gene Symbol: HTR1B
1 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSOKIG00005007222
Gene Symbol: HTR1B
3 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSOKIG00005005804
Gene Symbol: HTR1B
3 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSOKIG00005044972
Gene Symbol: HTR1B
1 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSOKIG00005002158
Gene Symbol: HTR1E
3 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSOKIG00005046214
Gene Symbol: HTR1E
1 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSOKIG00005008494
Gene Symbol: HTR1E
3 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSOKIG00005028884
Gene Symbol: HTR2A
3 Cross references
213 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSOKIG00005018533
Gene Symbol: HTR2A
3 Cross references
212 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSOKIG00005033181
Gene Symbol: HTR2B
3 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b-Like

Ensembl ID : ENSOKIG00005021078
Gene Symbol: LOC109902258
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).